By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tivorsan Pharmaceuticals, Inc. 

  Delaware    U.S.A.
Phone: n/a Fax: n/a



Company News
Tivorsan Pharmaceuticals, Inc. Granted FDA Orphan Drug Designation For Human Recombinant Biglycan In The Treatment Of Duchenne Muscular Dystrophy 8/15/2016 12:27:06 PM
Tivorsan Pharmaceuticals, Inc. Closes Private Placement 2/5/2016 9:15:40 AM
Tivorsan Pharmaceuticals, Inc. Names Business Leader James E. Connolly As CEO And Board Member 8/17/2015 7:45:54 AM
Tivorsan Pharmaceuticals, Inc. To Present at Biotech Showcase 2015 On Monday, January 12 1/9/2015 9:20:55 AM
Tivorsan Pharmaceuticals, Inc. Achieves Key Development Milestones Under Its Parent Project Muscular Dystrophy And Muscular Dystrophy Association Awards 1/8/2015 10:36:24 AM
Muscular Dystrophy Association Awards $1 Million to Tivorsan Pharmaceuticals, Inc. for Accelerating Pivotal Pre-Clinical Work on TVN-102 as a Potential Muscular Dystrophy Treatment 1/5/2012 11:06:24 AM
Tivorsan Pharmaceuticals, Inc.' Biglycan for Duchenne Muscular Dystrophy Named One of Windhover Information Inc.'s Top 10 “Hot Space” Projects to Watch 10/19/2011 10:34:38 AM
Tivorsan Pharmaceuticals, Inc.' Biglycan Protein Opens Unique Path for Preserving Muscle Function in Duchenne Muscular Dystrophy 12/28/2010 8:52:28 AM
Brown University Licenses Potential Muscular Dystrophy Treatment To Tivorsan Pharmaceuticals, Inc. 9/21/2010 9:28:59 AM